AEterna Zentaris (AEZS) Stock Price Up 5.6%

AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) rose 5.6% during trading on Thursday . The stock traded as high as $3.98 and last traded at $3.80. Approximately 1,022,863 shares changed hands during trading, an increase of 60% from the average daily volume of 639,047 shares. The stock had previously closed at $3.60.

AEZS has been the topic of several recent research reports. Zacks Investment Research raised shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Tuesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of AEterna Zentaris in a report on Wednesday, November 14th. ValuEngine raised shares of AEterna Zentaris from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Maxim Group set a $2.00 price objective on shares of AEterna Zentaris and gave the company a “buy” rating in a report on Thursday, December 20th. One research analyst has rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. AEterna Zentaris has an average rating of “Buy” and a consensus price target of $2.67.

The firm has a market capitalization of $65.76 million, a PE ratio of -2.81 and a beta of 0.92.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. AEterna Zentaris had a net margin of 34.40% and a return on equity of 83.33%. The firm had revenue of $0.66 million for the quarter. As a group, sell-side analysts expect that AEterna Zentaris Inc. will post 0.44 EPS for the current fiscal year.

A hedge fund recently bought a new stake in AEterna Zentaris stock. Virtu Financial LLC purchased a new position in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,028 shares of the biopharmaceutical company’s stock, valued at approximately $101,000. Virtu Financial LLC owned approximately 0.31% of AEterna Zentaris at the end of the most recent quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at

About AEterna Zentaris (NASDAQ:AEZS)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Further Reading: What is a balanced fund?

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply